Yabao Pharmaceutical Group Co (SHSE:600351) Other Current Payables: ¥148 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600351 Yabao Pharmaceutical Group Co Ltd SHSE:600351
67 GF Score
Price ¥6.91
GF Value ¥5.71
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Yabao Pharmaceutical Group Co Other Current Payables?

Yabao Pharmaceutical Group Co SHSE:600351 +6.80% 67 Other Current Payables is ¥148 Mil as of Jun. 2026. GuruFocus rates SHSE:600351 with a GF Score™ of 67/100 and a GF Value™ of ¥5.71 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Yabao Pharmaceutical Group Co's Other Current Payables for the quarter that ended in Jun. 2026 was ¥148 Mil.

Yabao Pharmaceutical Group Co's quarterly Other Current Payables increased from Dec. 2025 (¥128 Mil) to Mar. 2026 (¥140 Mil) and increased from Mar. 2026 (¥140 Mil) to Jun. 2026 (¥148 Mil).

Yabao Pharmaceutical Group Co's annual Other Current Payables declined from Dec. 2023 (¥248 Mil) to Dec. 2024 (¥189 Mil) and declined from Dec. 2024 (¥189 Mil) to Dec. 2025 (¥128 Mil).

Yabao Pharmaceutical Group Co Other Current Payables Related Terms

Yabao Pharmaceutical Group Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for Yabao Pharmaceutical Group Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yabao Pharmaceutical Group Co Other Current Payables Chart

Yabao Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 208.93 223.05 248.27 189.03 128.30

Yabao Pharmaceutical Group Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 197.48 157.36 128.30 139.63 148.06
SHSE:600351
67GF Score
Yabao Pharmaceutical Group Co Ltd SHSE:600351
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yabao Pharmaceutical Group Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ¥148 Mil mean?
Yabao Pharmaceutical Group Co (SHSE:600351) has a Other Current Payables of ¥148 Mil as of Jun. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Yabao Pharmaceutical Group Co and its competitors.
Is Yabao Pharmaceutical Group Co's Other Current Payables too high?
Yabao Pharmaceutical Group Co's current Other Current Payables is ¥148 Mil. Overall, Yabao Pharmaceutical Group Co has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yabao Pharmaceutical Group Co's Other Current Payables compare to ZTS?
Yabao Pharmaceutical Group Co's Other Current Payables of ¥148 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Yabao Pharmaceutical Group Co and its competitors. Yabao Pharmaceutical Group Co's current Other Current Payables is ¥148 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yabao Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co (SHSE:600351) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥5.71, compared to a current price of ¥6.91 — trading 21% above its estimated fair value. The current Other Current Payables is ¥148 Mil. Yabao Pharmaceutical Group Co's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Yabao Pharmaceutical Group Co (SHSE:600351), the current Other Current Payables is ¥148 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Yabao Pharmaceutical Group Co (SHSE:600351) Overvalued in 2026?

Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co stock appears to be overvalued. The current stock price of ¥6.91 is trading 21% above its estimated GF Value™ of ¥5.71. GuruFocus considers Yabao Pharmaceutical Group Co to be Modestly Overvalued.

Key valuation signals for SHSE:600351:

  • Other Current Payables: ¥148 Mil
  • GF Value™: ¥5.71 vs. price of ¥6.91 (21% above fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600351 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Yabao Pharmaceutical Group Co Business Description

Address No.43 Fumin Road, Ruicheng, Shanxi Province, Yuncheng, CHN, 044602
Yabao Pharmaceutical Group Co Ltd is engaged in the manufacture and operation of western and Chinese medicines, APIs, health care products, packing materials for medicine, and also engages in the planting and processing of medicinal herbs.
67GF Score

Get the complete analysis for SHSE:600351

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥6.91
Price
¥5.71
GF Value